Sugi Predict

Sugi Predict / Compounds / SCHEMBL95469

SCHEMBL95469

SCHEMBL95469

CC=CC(O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ ATM Q13315 1/20 0.60
▸ LMNA P02545 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.41
▸ ADRA2C P18825 2/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ TSHR P16473 2/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ RGS12 O14924 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL560387 1.00 MEN1 (0.60) MEN1KMT2AATMLMNAKDM4E
SCHEMBL22616865 1.00 MEN1 (0.60) MEN1KMT2AATMLMNAKDM4E
SCHEMBL9656438 0.85 LMNA (0.46) MEN1KMT2AATMLMNAKDM4E
SCHEMBL9656453 0.85 LMNA (0.46) MEN1KMT2AATMLMNAKDM4E
SCHEMBL2121638 0.80 LMNA (0.46) MEN1KMT2AATMLMNAKDM4E
SCHEMBL1944902 0.80 LMNA (0.46) MEN1KMT2AATMLMNAKDM4E
SCHEMBL9460583 0.80 LMNA (0.46) MEN1KMT2AATMLMNAKDM4E
SCHEMBL10996469 0.79 LMNA (0.45) MEN1KMT2AATMLMNAKDM4E
SCHEMBL31303664 0.79 ATM (0.53) MEN1KMT2AATMLMNAALDH1A1
SCHEMBL10996466 0.79 LMNA (0.45) MEN1KMT2AATMLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115805042-A Continuous flow reaction equipment suitable for suspended material under high temperature condition 上海合全药业股份有限公司 2023-03-17 — — CN disclosed
WO-2021112933-A1 COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2021-06-10 — — WO disclosed
WO-2020223489-A1 ROOM TEMPERATURE LIQUID METAL CATALYSTS AND METHODS OF USE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-11-05 — — WO disclosed
US-9486421-B2 Treatment of lung cells with histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2016-11-08 — — US disclosed
EP-3008078-A1 CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS Trustees of Boston College (US) 2016-04-20 — — EP disclosed
WO-2014201300-A1 CATALYSTS FOR EFFICIENT Z-SELECTIVE METATHESIS TRUSTEES OF BOSTON COLLEGE (US) 2014-12-18 — — WO disclosed
US-8569524-B2 Bis(tetrahydrofuran) compound, method for production of the compund, and use of the compound GLYTECH INC. (JP) 2013-10-29 — — US disclosed
US-8420698-B2 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC (US) 2013-04-16 — — US disclosed
EP-2123655-B1 BIS(TETRAHYDROFURAN) COMPOUND, METHOD FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND OTSUKA CHEMICAL CO LTD (JP) 2013-04-10 — — EP disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
US-20020143196-A1 Histone deacetylase inhibitors ERRANT GENE THERAPEUTICS, LLC 2002-10-03 — — US disclosed
US-20020143037-A1 Histone deacetylase inhibitors CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION 2002-10-03 — — US disclosed
US-20020143052-A1 Histone deacetylase inhibitors ANGELA CHEN SABELLA 2002-10-03 — — US disclosed
EP-1245571-A1 BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND Mitsui Chemicals, Inc. (JP) 2002-10-02 — — EP disclosed
CN-1338738-A Optical recording media and porphinoid compound MITSUI CHEMICALS INC (JP) 2002-03-06 — — CN disclosed
EP-1180765-A1 Optical recording medium and porphycene compound Mitsui Chemicals, Inc. (JP) 2002-02-20 — — EP disclosed
EP-0503884-B1 Optically active diphenylphosphino-binaphtyl compounds and catalytic transition metal complexes thereof TAKASAGO PERFUMERY CO LTD (JP) 1995-07-26 — — EP disclosed
WO-1995015301-A1 PREPARATION OF 4,4'-DIHYDROXY-ALPHA-ALKYLSTILBENES AND 4,4'-DIHYDROXY-ALPHA, ALPHA'-DIALKYLSTILBENES THE DOW CHEMICAL COMPANY (US) 1995-06-08 — — WO disclosed
US-5231202-A OPTICALLY ACTIVE TERTIARY PHOSPHINE COMPOUND AND TRANSITION METAL COMPLEX USING THE SAME AS LIGAND TAKASAGO INTERNATIONAL CORPORATION (JP) 1993-07-27 — — US disclosed
EP-0503884-A1 Optically active diphenylphosphino-binaphtyl compounds and catalytic transition metal complexes thereof Takasago International Corporation (JP) 1992-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143052-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC9 MEN1 1684/4885KMT2A 69/4885ATM 1453/4885
US-20020143196-A1 Histone deacetylase inhibitors HDAC1, HDAC11, HDAC5 MEN1 2334/4885KMT2A 77/4885ATM 1220/4885
US-20020143037-A1 Histone deacetylase inhibitors HDAC1, HDAC9, HDAC11 MEN1 1954/4885KMT2A 82/4885ATM 1130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.